Weighing the Rewards and Risks of Social Media for Retina Specialists

It can be worthwhile to build a presence after careful consideration.

By Susan L. Worley, contributing writer

Novartis Files for Approval of Brolucizumab for Wet AMD

The application is based on phase 3 data from the HAWK and HARRIER trials.

The Phase 3 Clinical Trial of Conbercept for Exudative AMD

The drug has the potential for extended treatment effect.

Why Vision Loss Persists in AMD

Exploring the reasons for decline in treated patients.

The Role of Laser for Retinal Vascular Disease in the Anti-VEGF Era

Safe and effective laser therapy continues to find its niche.

“Real-World” Outcomes of Anti-VEGF Therapy in Neovascular AMD in the United States

Differences between real-world and clinical trial outcomes continue to confound.

Mitochondrial Repair in Dry Age-Related Macular Degeneration

Mitochondria-targeting drugs have potential for future interventions.

UPFRONT: The Challenge of Undertreatment in Retina

SUBSPECIALTY NEWS: Gene therapy, stem-cell therapy, DR screening rates for the uninsured, and more.

CLINICAL TRIAL DOWNLOAD: Safety and Efficacy Data for Abicipar

Questions remain regarding inflammation rates.

CODING Q&A: Challenges in Remote Screening of Diabetic Patients

Part 2 of 2: coding and payer contracting.

RETINA CONVERSATIONS: A Conversation With Namrata Saroj, OD

Are investigator-initiated clinical trials for you?

NEW PRODUCT APPLICATIONS: Yutiq Implant for Chronic Noninfectious Posterior-Segment Uveitis

New uveitis treatment lasts longer, has fewer side effects.

CLINICAL TRIAL UPDATE